From Claude.ai Is ccr5 over expressed in crc as
Post# of 155128
(Total Views: 441)
Posted On: 05/20/2025 9:03:21 AM
From Claude.ai
Is ccr5 over expressed in crc as much as in Tnbc?
Based on the current research knowledge up to my October 2024 cutoff date, I can provide some insights on CCR5 expression in colorectal cancer (CRC) compared to triple-negative breast cancer (TNBC).
CCR5 (C-C chemokine receptor type 5) has been studied in both cancer types, but there are important differences in its expression patterns:
In TNBC, CCR5 is notably overexpressed and has been well-documented as playing a significant role in metastasis and cancer progression. Multiple studies have highlighted CCR5 as a potential therapeutic target specifically in TNBC due to its high expression levels.
In CRC, CCR5 is also overexpressed compared to normal tissue, but the degree of overexpression appears to be generally less pronounced than what's observed in TNBC. The role of CCR5 in CRC appears more variable and context-dependent.
Some key differences:
- TNBC shows consistently higher CCR5 expression across studies
- The prognostic significance of CCR5 overexpression appears stronger in TNBC
- Clinical trials targeting CCR5 have been more focused on TNBC than CRC
That said, CCR5 still plays an important role in CRC progression and metastasis, particularly through its interaction with its ligand CCL5 (RANTES), and remains a potential therapeutic target in CRC as well.
Would you like me to elaborate on the specific mechanisms of CCR5 involvement in either cancer type or the therapeutic implications of these differences?
Is ccr5 over expressed in crc as much as in Tnbc?
Based on the current research knowledge up to my October 2024 cutoff date, I can provide some insights on CCR5 expression in colorectal cancer (CRC) compared to triple-negative breast cancer (TNBC).
CCR5 (C-C chemokine receptor type 5) has been studied in both cancer types, but there are important differences in its expression patterns:
In TNBC, CCR5 is notably overexpressed and has been well-documented as playing a significant role in metastasis and cancer progression. Multiple studies have highlighted CCR5 as a potential therapeutic target specifically in TNBC due to its high expression levels.
In CRC, CCR5 is also overexpressed compared to normal tissue, but the degree of overexpression appears to be generally less pronounced than what's observed in TNBC. The role of CCR5 in CRC appears more variable and context-dependent.
Some key differences:
- TNBC shows consistently higher CCR5 expression across studies
- The prognostic significance of CCR5 overexpression appears stronger in TNBC
- Clinical trials targeting CCR5 have been more focused on TNBC than CRC
That said, CCR5 still plays an important role in CRC progression and metastasis, particularly through its interaction with its ligand CCL5 (RANTES), and remains a potential therapeutic target in CRC as well.
Would you like me to elaborate on the specific mechanisms of CCR5 involvement in either cancer type or the therapeutic implications of these differences?
(8)
(0)